Fate Therapeutics (FATE) Competitors $1.27 +0.02 (+1.60%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends FATE vs. ERAS, ORIC, TECX, VECT, KURA, CRGX, PHVS, HUMA, ANNX, and KROSShould you be buying Fate Therapeutics stock or one of its competitors? The main competitors of Fate Therapeutics include Erasca (ERAS), ORIC Pharmaceuticals (ORIC), Tectonic Therapeutic (TECX), VectivBio (VECT), Kura Oncology (KURA), CARGO Therapeutics (CRGX), Pharvaris (PHVS), Humacyte (HUMA), Annexon (ANNX), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry. Fate Therapeutics vs. Erasca ORIC Pharmaceuticals Tectonic Therapeutic VectivBio Kura Oncology CARGO Therapeutics Pharvaris Humacyte Annexon Keros Therapeutics Erasca (NASDAQ:ERAS) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, media sentiment, dividends, valuation, community ranking, analyst recommendations, risk and earnings. Does the media refer more to ERAS or FATE? In the previous week, Fate Therapeutics had 6 more articles in the media than Erasca. MarketBeat recorded 10 mentions for Fate Therapeutics and 4 mentions for Erasca. Erasca's average media sentiment score of 1.00 beat Fate Therapeutics' score of 0.64 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ERAS or FATE more profitable? Erasca has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,325.43%. Erasca's return on equity of -42.26% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets ErascaN/A -42.26% -34.97% Fate Therapeutics -1,325.43%-45.88%-33.95% Which has better earnings and valuation, ERAS or FATE? Erasca has higher earnings, but lower revenue than Fate Therapeutics. Erasca is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErascaN/AN/A-$125.04M-$0.83-2.23Fate Therapeutics$63.53M2.28-$160.93M-$1.65-0.77 Does the MarketBeat Community favor ERAS or FATE? Fate Therapeutics received 455 more outperform votes than Erasca when rated by MarketBeat users. However, 71.43% of users gave Erasca an outperform vote while only 68.09% of users gave Fate Therapeutics an outperform vote. CompanyUnderperformOutperformErascaOutperform Votes2571.43% Underperform Votes1028.57% Fate TherapeuticsOutperform Votes48068.09% Underperform Votes22531.91% Do analysts rate ERAS or FATE? Erasca currently has a consensus price target of $5.70, suggesting a potential upside of 208.11%. Fate Therapeutics has a consensus price target of $6.75, suggesting a potential upside of 431.50%. Given Fate Therapeutics' higher possible upside, analysts clearly believe Fate Therapeutics is more favorable than Erasca.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 Which has more volatility & risk, ERAS or FATE? Erasca has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Do institutionals & insiders believe in ERAS or FATE? 67.8% of Erasca shares are held by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are held by institutional investors. 21.5% of Erasca shares are held by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryErasca beats Fate Therapeutics on 9 of the 17 factors compared between the two stocks. Get Fate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FATE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FATE vs. The Competition Export to ExcelMetricFate TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$166.85M$2.96B$5.24B$8.95BDividend YieldN/A1.94%5.13%4.04%P/E Ratio-0.7745.5689.2317.34Price / Sales2.28265.291,255.2478.69Price / CashN/A192.9043.8235.97Price / Book0.343.965.324.79Net Income-$160.93M-$41.02M$122.69M$225.00M7 Day Performance-13.61%-1.74%-0.16%1.52%1 Month Performance-24.63%0.53%3.75%4.68%1 Year Performance-70.67%-1.69%27.40%20.89% Fate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FATEFate Therapeutics4.6459 of 5 stars$1.27+1.6%$6.75+431.5%-71.1%$166.85M$63.53M-0.77550Short Interest ↓News CoveragePositive NewsERASErasca3.0463 of 5 stars$2.08-12.2%$5.70+174.0%+1.6%$588.07MN/A-2.51126News CoverageORICORIC Pharmaceuticals3.7562 of 5 stars$8.17+2.6%$18.29+123.8%+3.0%$576.53MN/A-4.5480Analyst ForecastAnalyst RevisionTECXTectonic Therapeutic2.0414 of 5 stars$39.03-2.8%$72.25+85.1%N/A$575.81MN/A-6.63120Positive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030KURAKura Oncology4.3237 of 5 stars$7.15-2.3%$27.38+282.9%-50.8%$556.01MN/A-3.03130Short Interest ↑CRGXCARGO Therapeutics1.5852 of 5 stars$11.91-11.8%$31.80+167.0%-35.9%$548.19MN/A-2.80116Analyst RevisionPHVSPharvaris2.5394 of 5 stars$17.21-3.3%$39.25+128.1%-34.5%$547.97MN/A-6.1530Positive NewsGap DownHUMAHumacyte2.8364 of 5 stars$4.30-6.7%$13.71+218.9%+70.9%$541.19M$1.57M-3.21150Short Interest ↑Analyst RevisionANNXAnnexon2.3042 of 5 stars$4.84+0.2%$15.80+226.4%-8.7%$515.92MN/A-4.6160Short Interest ↑KROSKeros Therapeutics3.1844 of 5 stars$12.63-13.3%$75.00+493.8%-79.5%$511.60M$651,000.00-2.42100Analyst ForecastShort Interest ↑News CoverageGap Up Related Companies and Tools Related Companies Erasca Alternatives ORIC Pharmaceuticals Alternatives Tectonic Therapeutic Alternatives VectivBio Alternatives Kura Oncology Alternatives CARGO Therapeutics Alternatives Pharvaris Alternatives Humacyte Alternatives Annexon Alternatives Keros Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FATE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Fate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
